Due to transition in the journal platform, the previously submitted articles, which are under process can be re-submitted here for quick process, kindly co-operate

Biomedicine

Volume: 42 Issue: 3

  • Open Access
  • Short communications/brief reports

Doxycycline inhibits SARS-CoV-2 replication in vitro

Yethindra Vityala1, Tugolbai Tagaev2, Asel Imankulova3 Marat Kaliev4, Bakyt Orozalieva5, Mira Niyazalieva6, Altynai Zhumabekova7, Krishna Priya Kanteti8, Poojitha Sai Kuruva9

1Department of Pathology, International Higher School of Medicine, International University of Kyrgyzstan, Bishkek, Kyrgyzstan
2Department of Public Health and Healthcare, 3Office for Scientific-Innovative Research and Clinical Work, 5Department of Obstetrics and Gynecology No. 2, 6Department of Microbiology, Virology and Immunology, I.K. Akhunbaev Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan
4Scientific and Production Association "Preventive Medicine" of the Ministry of Health of the Kyrgyz Republic, Bishkek, Kyrgyzstan
7City Maternity Hospital No. 2, Bishkek, Kyrgyzstan
8Beihua University, Jilin, China
9Department of Pharmaceutical Analysis, Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam, Andhra Pradesh, India

Corresponding author: Yethindra Vityala, Email: [email protected]

Year: 2022, Page: 612-615, Doi: https://doi.org/10.51248/.v42i3.1635

Abstract

Introduction and Aim: We examined the effect of pre- and/or post-infection doxycycline on human nasal epithelial cell viability and SARS-CoV-2 (clinical strain IHUMI-3) replication in vitro.
Materials and Methods: Human nasal epithelial cells, an in vivo SARS-CoV-2 target, were derived from healthy donor nasal epithelial stem/progenitor cells via in vitro differentiation. The cells were exposed to doxycycline at 0, 0.1, 0.5, 1, 5, 10, 50, and 100 μM before and/or after IHUMI-3 inoculation to determine the optimal inhibitory concentration. Viral replication was evaluated using quantitative reverse-transcription PCR, and doxycycline 50% cytotoxic concentration (CC50) and half-maximal effective concentration (EC50) were calculated. The peak serum concentration (Cmax) resulting from typical oral (100 or 200 mg) or intravenous (100 mg) doxycycline doses was estimated, and the Cmax/EC50 ratio was calculated as an index of potential clinical utility.
Results: Doxycycline exhibited low cytotoxicity (CC50 > 100 μM) in human nasal epithelial cells and inhibited SARS-CoV-2 replication (EC50: 5.2 ± 3.3 μM) in a dose-dependent manner when administered pre- and/or post-infection. Reasonable oral or intravenous doses will help achieve effective concentrations in vivo.
Conclusion: Early administration of this well-characterized, safe, and accessible drug may limit person-to-person transmission and prevent progression to severe coronavirus disease.

Keywords: Doxycycline; COVID-19; SARS-CoV-2; in vitro.

Cite this article

Yethindra Vityala, Tugolbai Tagaev, Asel Imankulova Marat Kaliev, Bakyt Orozalieva, Mira Niyazalieva, Altynai Zhumabekova, Krishna Priya Kanteti, Poojitha Sai Kuruva. Doxycycline inhibits SARS-CoV-2 replication in vitro. Biomedicine: 2022; 42(3): 612-615

Views
39
Downloads
204
Citations